Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Prostate Cancer

  Free Subscription


3 Anticancer Res
1 BJU Int
3 BMC Urol
2 Cancer
1 Cancer Res
1 Clin Cancer Res
1 Eur J Radiol
1 Eur Radiol
5 Eur Urol
1 Int J Cancer
1 Mod Pathol
1 Oncogene
1 PLoS One
6 Prostate

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Anticancer Res

  1. MASUDA H, Amemiya Y, Yagisawa N, Arai T, et al
    Association Between Acute Kidney Injury and the Trendelenburg Position Angle During Robot-assisted Radical Prostatectomy.
    Anticancer Res. 2024;44:1767-1772.
    PubMed         Abstract available

  2. KASHIWAGI E, Kawahara T, Kinoshita F, Shiota M, et al
    The Role of Adipocytokines and their Receptors in Prostate Cancer: Adiponectin May Protect Against Progression.
    Anticancer Res. 2024;44:1369-1376.
    PubMed         Abstract available

  3. CHANG CC, Chiou JK, Lin CJ, Lu K, et al
    Machine-learning Algorithm-based Risk Prediction and Screening-detected Prostate Cancer in A Benign Prostate Hyperplasia Cohort.
    Anticancer Res. 2024;44:1683-1693.
    PubMed         Abstract available

    BJU Int

  4. PAK JS, Huang R, Huang WC, Lepor H, et al
    Interaction of patient age and high-grade prostate cancer on targeted biopsies of MRI suspicious lesions.
    BJU Int. 2024 Mar 27. doi: 10.1111/bju.16341.
    PubMed         Abstract available

    BMC Urol

  5. LAMA DJ, Thomas K, Vernez SL, Okunowo O, et al
    Minimally invasive cytoreductive radical prostatectomy, exploring the safety and feasibility of a single-port or multi-port robotic platform.
    BMC Urol. 2024;24:72.
    PubMed         Abstract available

  6. KRAUSEWITZ P, Buttner T, von Danwitz M, Weiten R, et al
    Elucidating the need for prostate cancer risk calculators in conjunction with mpMRI in initial risk assessment before prostate biopsy at a tertiary prostate cancer center.
    BMC Urol. 2024;24:71.
    PubMed         Abstract available

  7. ALBO G, Gallioli A, Ripa F, De Lorenzis E, et al
    Extended pelvic lymph node dissection during robotic prostatectomy: antegrade versus retrograde technique.
    BMC Urol. 2024;24:64.
    PubMed         Abstract available


  8. SOLANKI AJ, Kamrava M, Posadas EM, Freedland SJ, et al
    A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer.
    Cancer. 2024 Mar 26. doi: 10.1002/cncr.35285.
    PubMed         Abstract available

  9. PEPPONE LJ, Kleckner AS, Fung C, Puzas JE, et al
    High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT.
    Cancer. 2024 Mar 23. doi: 10.1002/cncr.35275.
    PubMed         Abstract available

    Cancer Res

  10. SHU F, Liu H, Chen X, Liu Y, et al
    m6A modification promotes EMT and metastasis of castration-resistant prostate cancer by upregulating NFIB.
    Cancer Res. 2024 Mar 27. doi: 10.1158/0008-5472.CAN-23-1954.
    PubMed         Abstract available

    Clin Cancer Res

  11. DESAI KB, Serritella AV, Stadler WM, O'Donnell PH, et al
    A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.
    Clin Cancer Res. 2024 Mar 27. doi: 10.1158/1078-0432.CCR-23-3636.
    PubMed         Abstract available

    Eur J Radiol

  12. QUENTIN M, Boschheidgen M, Radtke JP, Spohn F, et al
    MRI in-bore biopsy following MRI/US fusion-guided biopsy in patients with persistent suspicion of clinically significant prostate cancer.
    Eur J Radiol. 2024;175:111436.
    PubMed         Abstract available

    Eur Radiol

  13. GIROMETTI R, Giganti F
    Active surveillance of prostate cancer: MRI and beyond.
    Eur Radiol. 2024 Mar 28. doi: 10.1007/s00330-024-10717.

    Eur Urol

  14. BURGER M
    Re: First-in-human Evaluation of a Prostate-specific Membrane Antigen-targeted Near-infrared Fluorescent Small Molecule for Fluorescence-based Identification of Prostate Cancer in Patients with High-risk Prostate Cancer Undergoing Robotic-assisted Pro
    Eur Urol. 2024 Mar 22:S0302-2838(24)02205-X. doi: 10.1016/j.eururo.2024.

  15. DE MEERLEER G, Joniau S, Benijts J, Rans K, et al
    Oligometastatic Recurrent Prostate Cancer: Whether To Intensify Treatment or Not.
    Eur Urol. 2024 Mar 22:S0302-2838(24)02238-3. doi: 10.1016/j.eururo.2024.

  16. WINDISCH O, Valerio M
    Re: Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localised Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-year Experience.
    Eur Urol. 2024 Mar 26:S0302-2838(24)02208-5. doi: 10.1016/j.eururo.2024.

  17. WASSERSUG RJ, Schellhammer PF, Wibowo E
    Re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7.
    Eur Urol. 2024 Mar 26:S0302-2838(24)02233-4. doi: 10.1016/j.eururo.2024.

    Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024
    Eur Urol. 2024 Mar 26:S0302-2838(24)02240-1. doi: 10.1016/j.eururo.2024.

    Int J Cancer

  19. STROMBERG U, Berglund A, Carlsson S, Thellenberg Karlsson C, et al
    Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden.
    Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34932.
    PubMed         Abstract available

    Mod Pathol

  20. IRMAKCI I, Nateghi R, Zhou R, Vescovo M, et al
    Tissue Contamination Challenges the Credibility of Machine Learning Models in Real World Digital Pathology.
    Mod Pathol. 2024;37:100422.
    PubMed         Abstract available


  21. YI Q, Han X, Yu HG, Chen HY, et al
    SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain.
    Oncogene. 2024 Mar 26. doi: 10.1038/s41388-024-02944.
    PubMed         Abstract available

    PLoS One

  22. CHEN LC, Yang HJ, Yu BH, Lee MS, et al
    Association of spironolactone use with risk of urinary tract cancer in the general population: A matched population-based cohort study.
    PLoS One. 2024;19:e0300391.
    PubMed         Abstract available


  23. SHAHAIT M, Hakansson AK, Daniel RE, Hosny K, et al
    Quantification and molecular correlates of tertiary lymphoid structures in primary prostate cancer.
    Prostate. 2024 Mar 27. doi: 10.1002/pros.24684.
    PubMed         Abstract available

  24. MAHON KL, Sutherland SI, Lin HM, Stockler MR, et al
    Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
    Prostate. 2024 Mar 27. doi: 10.1002/pros.24691.
    PubMed         Abstract available

  25. DWINA Y, Zaid LSM, Saraswati M, Rachmadi L, et al
    CD44 and CD133 protein expression might serve as a prognostic factor for early occurrence castration-resistant prostate cancer.
    Prostate. 2024 Mar 25. doi: 10.1002/pros.24690.
    PubMed         Abstract available

  26. ONAL C, Guler OC, Erbay G, Elmali A, et al
    The effect of dose-escalation radiotherapy with simultaneous-integrated-boost on the use of short-term androgen deprivation therapy in patients with intermediate risk prostate cancer.
    Prostate. 2024 Mar 25. doi: 10.1002/pros.24693.
    PubMed         Abstract available

  27. QAZI SU, Altaf Z, Zafar M, Tariq MA, et al
    Development of depression in patients using androgen deprivation therapy: A systemic review and meta-analysis.
    Prostate. 2024;84:525-538.
    PubMed         Abstract available

  28. ROMANO L, Napolitano L, Crocetto F, Sciorio C, et al
    Prostate and gut: Any relationship? A narrative review on the available evidence and putative mechanisms.
    Prostate. 2024;84:513-524.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.